Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fujifilm Diosynth Biotechnologies Doubles Laboratory Footprint in North Carolina | Contract Pharma

What are you searching for?

Sign in

Fujifilm Diosynth Biotechnologies Doubles Laboratory Footprint in North Carolina

Expands the sites’ process development, process characterization and analytical services and adds approximately 145 positions by 2024.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, is expanding its BioProcess Innovation Center (BIC) in Research Triangle Park (RTP). Through the expansion, Fujifilm Diosynth Biotechnologies will add approximately 145 skilled positions including researchers and scientists to the RTP site by 2024.
 
The expansion will double Fujifilm Diosynth Biotechnologies’ capacity to support process characterization programs and complements the enhanced and now operational capabilities at Fujifilm Diosynth Biotechnologies’ UK facility, announced in December 2020. In addition, this expansion will allow Fujifilm Diosynth Biotechnologies to better support its partners in discovering the attributes that make each protein unique and better guide clinical process development to create more robust commercial processes. The expansion will include the addition of roughly 89,000 square feet  of laboratory space equipped with comprehensive, state of the art analytical instrumentation, high throughput bioprocessing equipment and automation technologies. The expanded capacity is expected to be operational by mid-2024.
 
“As leaders in process development, we are delighted to be adding this additional capacity to support our growing pipeline of customers,” said Christine Vannais, chief operating officer, Fujifilm Diosynth Biotechnologies, RTP, North Carolina. “The cutting-edge laboratory equipment and automation tools, combined with the deep technical expertise of our scientific community will allow us to better serve our partners to rapidly generate and assess data to understand complex molecules, along with the processes used in their manufacture.”
 
The BIC originally opened in May 2016 as a three-story, 62,000 square foot facility with the purpose of process invention, process design and development, and product characterization for Fujifilm Diosynth Biotechnologies’ clients.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics